Search results
Results From The WOW.Com Content Network
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, Mainland China in December 2019 [4] and was confirmed to have spread to Indonesia on 2 March 2020. [5] COVID-19 vaccination in Indonesia will cover more than 75% of overall Indonesian population ...
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria [6] and Covishield, [7] is a viral vector vaccine [8] produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8] [9] [10] Finland, Denmark, and Norway suspended the use of the ...
The COVID-19 Immunisation Task Force, or CITF (Malay: Jawatankuasa Petugas Khas Imunisasi COVID-19 ), is a committee that was established based on the decision made during a cabinet meeting held on 20 January 2021 by the Government of Malaysia to ensure that the vaccines' distribution is done flawlessly.
e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33] [34] [35] using as a vector the modified chimpanzee ...
v. t. e. COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country .
Attenuated vaccine. An attenuated vaccine (or a live attenuated vaccine, LAV) is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). [1] Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. [2]
Sputnik V ( Russian: Спутник V, the brand name from the Russian Direct Investment Fund or RDIF) or Gam-COVID-Vac ( Russian: Гам-КОВИД-Вак, the name under which it is legally registered and produced [3]) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and ...
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). [2] The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. [3] In October 2021 CureVac abandoned further development and production plans for ...